

mCRPC treatment: Current advances and future horizons

Highlights from a roundtable discussion of key data presented at ASCO and ASCO GU in 2024



Dr Neeraj Agarwal



Professor Axel Merseburger




Dr Bárbara Vieira Lima Aguiar Melão



Professor Karim Fizazi

Olaparib in mCRPC with HRRm

How do real-world data compare with results of PROfound?



Real-world OS from olaparib initiation was considered “similar” to PROfound*, despite later-line use of olaparib in the real world³

Radioligands for mCRPC: Impact on HRQoL

PSMAfore:

Second interim analysis⁴



Median duration of exposure was 8.4 months (¹⁷⁷Lu-PSMA-617) and 6.5 months (ARPI change)



Prolonged rPFS with ¹⁷⁷Lu-PSMA-617 vs ARPI



Delayed worsening of pain and HRQoL with ¹⁷⁷Lu-PSMA-617, compared with changing ARPIs

Combination PARPi + ARPIs in first-line mCRPC



BRCAAway⁵

Abiraterone + olaparib (vs abiraterone or olaparib)

PFS results indicate benefit from combination of ARPI and olaparib in people with ATM, BRCA1, or BRCA2 mutations

PROpel⁶

Olaparib + abiraterone (vs placebo + abiraterone)

TALAPRO-2⁸

Talazoparib + enzalutamide (vs placebo + enzalutamide)

Matching-adjusted indirect comparison: TALAPRO-2 and PROpel⁷

No significant difference in OS and rPFS between

- Talazoparib + enzalutamide
- Olaparib + abiraterone

Prognostic biomarkers in mCRPC



“ctDNA burden may emerge as a prognostic biomarker in mCRPC patients treated with PARPi + ARPI combination”
Dr Melão on results of a retrospective analysis of TALAPRO-2⁹

Second-line hormonal therapy for mCRPC

CONTACT-02¹⁰

Cabozantinib + atezolizumab (vs abiraterone + prednisone or enzalutamide)

Significantly improved PFS with cabozantinib + atezolizumab (vs alternative combined therapies)

Therapies in development for mCRPC

ARV-766 (PROTAC AR degrader)

Initial phase 1/2 safety and tolerability results available (N=103)¹¹

JNJ-69086420 (²²⁵Ac-labeled anti-hK2 Ab)

Phase 1 first-in-human safety and dosing data available (N=67)¹²

First in class

*Raw, unadjusted indirect comparison.³

²²⁵Ac, actinium-225; Ab, antibodies; ARPI, androgen receptor pathway inhibitor; AR, androgen receptor; ATM, ataxia telangiectasia mutated; ASCO, American Society of Clinical Oncology; ASCO GU, ASCO Genitourinary Cancers Symposium; BRCA1/2, BRCA1/2; ctdNA, circulating tumor DNA; hK2, human kallikrein-2; HRQoL, health-related quality of life; HRRm, homologous recombination repair mutation; mCRPC, metastatic castration-resistant prostate cancer; OS, overall survival; PARPi, poly-ADP ribose polymerase inhibitor; PFS, progression-free survival; PROTAC, proteolysis-targeting chimera; rPFS, radiographic PFS.

References: 1. Kariburyo-Yay F, et al. Abstract 5054. ASCO 2024. May 29, 2024; Chicago, USA. DOI:10.1200/JCO.2024.42.16_suppl.5054. 2. Kariburyo-Yay F, et al. Poster 460. ASCO 2024. https://meetings.asco.org/abstracts-presentations/234444/poster. May 29, 2024; Chicago, USA. 3. Hussain M, et al. NEJM. 2020;383:2345–2357. 4. Fizazi K, et al. Abstract 5003. ASCO 2024. May 29, 2024; Chicago, USA. DOI:10.1200/JCO.2024.42.16_suppl.5003. 5. Hussain MHA, et al. Abstract 19. ASCO GU 2024. DOI:10.1200/JCO.2024.42.4_suppl.19. Jan 29, 2024; Chicago, USA. 6. Shore ND, et al. Abstract 165. ASCO GU 2024. DOI:10.1200/JCO.2024.42.4_suppl.165. Jan 29, 2024. Chicago, USA. 7. Castro E, et al. Abstract 5063. ASCO 2024. DOI:10.1200/JCO.2024.42.16_suppl.5063. May 29, 2024; Chicago, USA. 8. Fizazi K, et al. Nat Med. 2023; 30:257–264. 9. Azad A, et al. Abstract 5020. ASCO 2024. DOI:10.1200/JCO.2024.42.4_suppl.5020. May 29, 2024; Chicago, USA. 10. Agarwal N, et al. Abstract 18. ASCO GU 2024. Jan 29, 2024; Chicago, USA. DOI:10.1200/JCO.2024.42.4_suppl.18. 11. Petrylak DP, et al. Abstract 5011. ASCO 2024. DOI:10.1200/JCO.2024.42.16_suppl.5011. May 29, 2024; Chicago, USA. 12. Morris MJ, et al. Abstract 5010. ASCO 2024. DOI:10.1200/JCO.2024.42.16_suppl.5010. May 29, 2024; Chicago, USA.

Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.

